Immutep (NASDAQ:IMMP) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Immutep (NASDAQ:IMMP) had its target price boosted by research analysts at Robert W. Baird from $6.00 to $7.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s target price indicates a potential upside of 241.46% from the company’s current price.

Immutep Trading Down 1.9 %

IMMP stock opened at $2.05 on Friday. Immutep has a fifty-two week low of $1.58 and a fifty-two week high of $3.34. The business’s 50 day moving average price is $2.10 and its two-hundred day moving average price is $2.33. The company has a current ratio of 18.25, a quick ratio of 18.25 and a debt-to-equity ratio of 0.01.

Hedge Funds Weigh In On Immutep

A number of institutional investors have recently added to or reduced their stakes in IMMP. Meridian Wealth Management LLC grew its position in shares of Immutep by 4.5% in the 3rd quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock worth $881,000 after buying an additional 17,250 shares during the period. XY Capital Ltd boosted its stake in Immutep by 108.3% during the third quarter. XY Capital Ltd now owns 108,349 shares of the biotechnology company’s stock worth $239,000 after acquiring an additional 56,344 shares in the last quarter. XTX Topco Ltd purchased a new stake in Immutep in the second quarter worth about $26,000. Virtu Financial LLC increased its stake in shares of Immutep by 269.4% during the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 32,864 shares in the last quarter. Finally, Oracle Investment Management Inc. lifted its holdings in shares of Immutep by 9.4% during the first quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock valued at $1,316,000 after purchasing an additional 48,449 shares during the last quarter. Institutional investors own 2.32% of the company’s stock.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.